A long-term, post-treatment safety follow-up, multi-center study in patients with type 2 diabetes mellitus from the GALLANT, GALLEX or ARMOR studies
Phase of Trial: Phase III
Latest Information Update: 04 Mar 2016
At a glance
- Drugs Tesaglitazar (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms G-PLUS
- Sponsors AstraZeneca
- 29 Nov 2007 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 28 Aug 2006 Status change
- 29 Mar 2006 New trial record.